The BioFire® FilmArray®
Gastrointestinal (GI) Panel

Traditional approaches to identify pathogens responsible for enteric infections can be time consuming and lack sensitivity, which can lead to misdiagnosis and mistreatment.1,2


The BioFire GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis – all from one patient sample, one easy to use reagent, and results are available in about an hour.




Overall 98.5% Sensitivity and 99.2% Specificity9
Sample Type: Stool in Cary Blair



● Campylobacter (jejuni, coli, and upsaliensis)
● Clostridium difficile
(toxin A/B)
● Plesiomonas shigelloides
● Salmonella
● Yersinia enterocolitica
● Vibrio (parahaemolyticus, vulnificus, and cholerae)
● Vibrio cholerae



● Enteroaggregative E. coli (EAEC)
● Enteropathogenic E. coli (EPEC)
● Enterotoxigenic E. coli (ETEC) lt/st
● Shiga-like toxin-producing E. coli (STEC) stx1/stx2
● E. coli O157
● Shigella/Enteroinvasive E. coli (EIEC)



● Cryptosporidium
● Cyclospora cayetanensis
● Entamoeba histolytica
● Giardia lamblia


● Adenovirus F40/41
● Astrovirus
● Norovirus GI/GII
● Rotavirus A
● Sapovirus (I, II, IV, and V)

Workflow Benefits

Syndromic Testing with the BioFire GI Panel can provide a streamlined workflow, as well as faster and more comprehensive results.2,3,4,5

  • Number of additional stool tests decreased from 3 to about 16
  • Reduced number of send-out tests7
  • The average time-to-result was reduced by 84% compared to traditional methods6

Clinical Benefits

Clinicians rarely receive accurate or timely answers with traditional stool testing methods and often have to make patient management decisions without a laboratory result. With the BioFire GI Panel, timely and accurate results are provided that have been demonstrated to lead to more targeted therapy, as well as:2,8

  • Reduced length of stay6
  • Reduced downstream radiologic tests, such as CT scans, X-rays, and ultrasounds6
  • Reduction in time from sample collection to antimicrobial therapy8

Who should be tested on the BioFire GI Panel?

The American College of Gastroenterology (ACG) recommends the following patients to be tested by culture or culture-independent methods, like the BioFire GI Panel:2

  • Individuals with moderate-to-severe symptoms associated with acute diarrhea
  • Individuals at high risk of spreading disease to others and during known or suspected outbreaks
  • Individuals with dysentery
  • Individuals with acute diarrhea lasting >7 days
  • Immunocompromised individuals with acute diarrhea*

*The performance of this test has not been evaluated for immunocompromised individuals.

“I have extensive experience with the [FilmArray]. I truly believe that [it is] absolutely essential in my clinical practice. The information can assist in antibiotic stewardship…it is rapid and accurate.”

– Marian Regional Medical Center
Santa Maria, CA


Publications and Posters

Supporting Documents

Other Available
BioFire® FilmArray® Panels


  1. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK. 2001. Practice Guidelines for the Management of Infectious Diarrhea. Clin Infect Dis. 2001;32:331-50.
  2. Riddle MS, DuPont HL, Connor BA. 2016. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. Am J Gastroenterol. 111:602–622.
  3. Bourzac K, Holmberg K, Stockmann C, Cohen D, Leber A, Daly J, Jackson J, Kanwar N, Selvarangan R, Bender J, Dien Bard J, Festekjian A, Duffy S, Pavia A, Chapin K. 2016. Missed Opportunities for Treatment: Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis (GE): The FilmArray® GI Panel IMPACT Study, abstr 290. American Society for Microbiology 2016, Boston, MA.
  4. Spina A, Kerr KG, Cormican M, Barbut F, Eigentler A, Zerva L, Tassios P, Popescu GA, Rafila A, Eerola E, Batista J, Maass M, Aschbacher R, Olsen KE, Allerberger F. 2015. Spectrum of enteropathogens detected by the FilmArray GI Panel in a multicentre study of community-acquired gastroenteritis. Clin Microbiol Infect. 21(8):719-28.
  5. Khare R, Espy MJ, Cebelinski E, Boxrud D, Sloan LM, Cunningham SA, Pritt BS, Patel R, Binnicker MJ. Comparative Evaluation of Two Commercial Multiplex Panels for Detection of Gastrointestinal Pathogens by
    Use of Clinical Stool Specimens. J Clin Microbiol. 2014 Oct;52(10):3667-73.
  6. Beal S., Tremblay E., Toffel S., Velez L., Rand K. A gastronintestinal PCR panel improves clinical management and lowers healthcare costs. American Association for Clinical Chemistry, August 2017.
  7. Rand KH, Tremblay EE, Hoidal M, Fisher LB, Grau KR, Karst SM. 2015. Multiplex gastrointestinal pathogen panels: implications for infection control. Diagnostic microbiology and infectious disease. 30;82(2):154-7.
  8. Cybulski R, Bateman A, Bourassa L, Bryan A, Beail B, Matsumoto J, Cookson B, Fang FC; Clinical impact of a Multiplex Gastrointestinal PCR Panel in Patients with Acute Gastroenteritis. 2018. Clinical Infectious Diseases, ciy357,
  9. Data on file at BioFire Diagnostics.